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Yihong Wang1*, Qicai He2, Wei Shi1, Jun Wang3 and Hongxiu Ji1,4Abstract
We encountered an extremely rare case of multiple pulmonary sclerosing hemangiomas (PSH) with extensive
neuroendocrine lesions, including pulmonary neuroendocrine cell (PNC) hyperplasia, multiple carcinoid tumorlets
and typical carcinoid tumors within one pulmonary lobe. To the best of our knowledge, this is the first reported
case in the English medical literature of PSH combined and admixed with carcinoid tumors and extensive
neuroendocrine proliferation. This case is noteworthy for several reasons. First, the lesion is multi-nodular and
unusually large for a typical PSH, which may mimic malignancy on imaging studies and cause diagnostic difficulties.
Second, sampling bias may lead to diagnostic errors for a lesion containing two different types of neoplasms.
Third, our case displays a rare mixed and mosaic pattern of PSH with a full spectrum of pulmonary neuroendocrine
lesions, which may imply a potential intrinsic association in pathogenesis between PSH and concomitant
neuroendocrine neoplasms. The clinical implication of multiple PSHs is also discussed.
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Pulmonary sclerosing hemangioma (PSH) was first de-
scribed by Liebow and Hubbell in 1956 as an uncommon
neoplasm originally hypothesized of to be vascular origin
[1]. It typically presents as a solitary and slow-growing
mass, demonstrating a benign clinical course. However,
multiplicity could be a very unusual presentation and its
histopathogenesis and biological behavior are still unclear
[2-5]. PSH consists of two distinctive types of tumor cells,
the surface cuboidal cells and the round stromal cells,
forming a mixture of sclerotic, hemorrhagic, papillary and
solid histologic patterns. Given the unique constellation of
two types of tumor cells respectively harboring different
histological features of PSH, a variety of pathogenesis the-
ories other than vascular origin was postulated, including
mesothelial, mesenchymal and epithelial origin. Some pre-
vious studies revealed neuroendocrine features in certain
PSHs, suggesting the possibility of their neuroendocrine* Correspondence: wyh_annie@aliyun.com
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unless otherwise stated.origin [6,7]. To date, most scholars have reached the con-
sensus that PSH derives from primitive respiratory epithe-
lium [8] while the mechanism behind its neuroendocrine
differentiation remains controversial. Although rare, car-
cinoid tumorlets or typical carcinoid tumors have been
previously described as concomitant with PSH, but as sep-
arate lesions [8,9]. Whether this incidental concurrence
shares a common underlying cause is still a mystery. A
PSH intimately mixed with multiple carcinoid tumorlets
or typical carcinoid tumors has never been reported in the
English medical literature. Here we describe a case of PSH
with a full spectrum of pulmonary neuroendocrine lesions,
which includes pulmonary neuroendocrine cell hyperpla-
sia, multiple carcinoid tumorlets and carcinoid tumors.Case presentation
The patient was a 50-year old non-smoking Chinese
woman who presented with recurrent dry cough with
chest pain and dyspnea for over 7 years. Her symptoms
aggravated in the recent two weeks. She had never lived in
high altitude areas and had no history of lung diseases.
Physical examination and laboratory results were unre-
markable. A pre-operative chest computed tomographytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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middle lobe, with relatively smooth borders and calcified
dots in focal areas (Figure 1A). The multiple nodular fash-
ion of the lesion aroused suspicion for malignancy. A sub-
sequent CT-guided fine needle biopsy showed pulmonary
neuroendocrine cell (PNC) hyperplasia. This was followed
by an open thoracotomy with right middle lobectomy,
which was notable for a large multi-nodular lesion measur-
ing 12 cm, occupying the subpleura and pulmonary paren-
chyma (Figure 1B). No gross pleural, hilar or mediastinal
dissemination was detected during surgery.
Macroscopically, the right middle lobe of lung measured
12.2 × 6 × 3.8 cm, with a solid, gray-to-white regional area
of approximately 9.0 × 4.2 × 2.0 cm. There were multiple
rubbery, hard, round nodules of varying sizes seen both
beneath the pleura and within the pulmonary parenchyma.
The nodules were well-circumscribed and unencapsulated,
measuring from 0.3 cm to 2.2 cm and some of these
merged into each other. The cut surface was gray-white,
solid, with partially hard areas in the larger nodules.
Microscopically, the neoplasm consisted of multiple
variable-sized nodules (Figure 2A), some of which coa-
lesced. Most of the lesion displayed a typical architecture
of PSH, which generally comprises four histologic patterns:
sclerotic, hemorrhagic, papillary and solid (Figure 2B). In
the sclerotic areas, scattered calcifications were identified
resulting from calcium deposition in sclerotic fibrous
stroma. A constellation of two types of tumor cells were
found in these areas. One type was the surface cuboidal
cells lining papillary or glandular structures and the other
was the relatively uniform round to polygonal cells be-
neath the epithelial cells or arranged as solid sheets or
nests. There were abundant and delicate capillaries dir-
ectly connected to the round neoplastic cells with very
scanty fibrous stroma. The cuboidal cells were positive forFigure 1 A solid, gray-to-white legional area in right middle lobe lung
density (arrow) in the medial segment of right middle lobe, with relatively
specimen shows multiple nodules of varying sizes seen both beneath subp
measures 9.0 cm in greatest dimension and is composed of nodules ranginpancytokeratin, thyroid transcription factor-1 (TTF-1) and
epithelial membrane antigen (EMA), whereas the round
cells were pancytokeratin negative, but TTF-1 and EMA
positive by immunohistochemistry (Figure 2C).
Also noted scattered within and intermingled with the
PSH, was a distinct spectrum of diffuse PNC proliferation.
This included lesions of typical carcinoid tumors (>5 mm)
(Figure 3A), carcinoid tumorlets (lesions 2 to 5 mm) and
extensive neuroendocrine cell hyperplasia (Figure 3B,C).
Extensive minute foci of neuroendocrine cell proliferation
were found within or closely adjacent to the PSH struc-
ture. No PNC proliferation was appreciated in the pul-
monary lobe without presence of PSH.
The cells in the neuroendocrine lesions showed immu-
nohistochemical reactivity with TTF-1, chromogranin A
(CgA), synaptophysin (SyN) and CD56, but were negative
for pancytokeratin or S-100. Some hyperplasic foci of neu-
roendocrine cells were situated beneath but confined to
the airway epithelium, while others penetrated through
the basement membrane and infiltrated the lung paren-
chyma to form multiple nodules and cellular nests with
variable sizes, some of which display rosette features. Most
PNC neoplasms measured from 2.0 to 4.0 mm, with
two of them measured 5.2 mm and 5.5 mm, respectively,
which qualified for carcinoid tumors. No mitosis or necro-
sis was found in the carcinoid tumors. A Ki-67 index was
low (<2%,) excluding higher grade neuroendocrine carcin-
oma, such as atypical carcinoid tumor and small cell car-
cinoma. In contrast, the surface epithelial and round
stromal cells of PSH area were completely negative for
neuroendocrine markers, which are CgA, SyN and CD56
(Figure 3D). There was no metastasis found in hilar and
mediastinal lymph nodes. The patient received no adju-
vant therapy after surgery and has remained disease-free
during a 14-month follow-up.. (A) Computed tomography scan demonstrates nodular and irregular
smooth borders and focal dot-like calcifications. (B) Resected lung
leural and within the pulmonary parenchyma. The overall lesion
g from 0.3 cm to 2.2 cm.
Figure 2 Histologic and immunohistochemistry findings of pulmonary sclerosing hemangioma (PSH). (A) Multi-nodular PSH, with fibrous
septae dividing different nodules. (B) Various histologic patterns of PSH (papillary, sclerotic, solid and hemorrhagic) (H&E stain, original magnification,
(A)× 20, (B)× 40). (C) Characteristic immunostaining profile of PSH, both surface cells and round stromal cells are positive for epithelial marker epithelial
membrane antigen (left panel) and thyroid transcription factor-1 (right panel), but only surface cells are positive for pancytokeratin (another epithelial
marker) (middle panel) (Polymer method; original magnification, ×100).
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This is a rare case of multiple neuroendocrine tumors and
extensive neuroendocrine cell proliferation, not only con-
current with but also located within PSH. PSH was first
described by Liebow and Hubbell in 1956 as an uncom-
mon neoplasm of vascular origin [1] and different scholars
have since investigated its nature in terms of clinical pres-
entation, morphology, phenotype and prognosis thereafter.
Its clinical symptoms include cough, hemoptysis, chest
pain and dyspnea although most patients are asymptom-
atic, their tumors being identified incidentally. It typically
affects middle-aged adults with female predominance, pre-
sents as a solitary and slow growing mass located in the
lung periphery, demonstrating a benign clinical course [8].However, occasional recurrence and progressive pleural
dissemination in post-operative follow-up of PSH patients
have been previously reported [10,11]. Regional lymph
node metastasis and rare locally infiltrative growth to
pleura may suggest low malignant potential for the minor-
ity of PSH [10-13]. Histologically, PSH consists of two types
of tumor cells, the surface cuboidal cells and the round
stromal cells, forming a mixture of sclerotic, hemorrhagic,
papillary and solid patterns. By immunohistochemistry,
both the surface cell and round cell populations express
TTF-1 and EMA in the majority of cases, with only
surface cells exhibiting pancytokeratin positivity. As
suggested by a large series of immunohistochemistry
analyses [6], most scholars have reached the consensus
Figure 3 Spectrum of pulmonary neuroendocrine cell (PNC) proliferation and its intimate association with PSH. (A) Typical carcinoid
tumor, 5.5 mm in size, composed of uniform short-spindled or oval shaped cells. (B) Carcinoid tumorlet admixed with PSH in a single nodule,
with PSH on the left (dotted arrow), tumorlet on the right (arrow). (C) Foci of PNC proliferation highlighted by synaptophysin staining beneath
airway epithelium (arrows). (D) Positive chromogranin staining in a tumorlet, in contrast to surrounding negative PSH areas (H&E stain and
polymer method, original magnification, (A) and (D) × 20, (B) and (C) × 40).
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In addition, some recent molecular studies further con-
firmed the clonal and neoplastic nature of both compo-
nents of PSH and their common origin [14-17].
Given the mixed appearance of PSH and PNC lesions in
our case, it was first assumed that it may represent a ‘colli-
sion tumor’, that is a PSH coincidentally developing in a
lung lobe that contains diffuse PNC hyperplasia, such as in
the very rare condition of diffuse idiopathic neuroendocrine
cell hyperplasia (DIPNECH), a preinvasive precursor to
tumorlets and carcinoid tumors and defined by the World
Health Organization. DIPNECH develops without predis-
posing conditions and affects similar populations as PSH,
which are non-smoking and middle-aged women [8,18-20].
However, PNC hyperplasia is also observed in individuals
who live at high altitude, in cigarette smokers, in various
chronic lung diseases and associated with distortion of the
lung microstructure and with hypoxia, but the definite
cause for hyperplasia is just beginning to be understood
[18,21]. Thus, another possible explanation for ‘collision’ isthat PSH tumor cells, devoid of normal respiratory epithe-
lium function, somehow disrupted local airway homeostasis
and caused damage to adjacent alveolar epithelium. The
slow-progressing course of the neoplasm delivered pro-
longed insult to the airway epithelium in the similar fashion
as other forms of chronic lung diseases. PNCs, as providers
of the airway epithelium stem cell niche [22,23], may be ac-
tivated to proliferate in order to restore the damaged epi-
thelium. In addition, decreased pulmonary compliance and
ventilation disorder could occur as PSH grows to a consid-
erable size and lead to local intrapulmonary hypoxia. It is
possible that PNCs, known as chemoreceptors sensitive to
hypoxia [24] would then be stimulated to overproduce vari-
ous bioactive peptides, including gastrin-releasing peptide,
which may in return promote further proliferation and dif-
ferentiation of PNCs [21,22]. Moreover, hypoxia may trigger
a cascade of molecular events that can drive tumorigenesis
of pulmonary carcinoids [25,26]. Over time, PSH could in-
duce excessive PNC proliferation, which would then mani-
fest clinically as mixed PSH and PNC tumors.
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may also suggest that it may represent ‘one’ tumor, an
example of clonal expansion of a primitive respiratory
epithelial cell that is capable of divergent cellular differ-
entiation, not only to the two distinct cell types of PSH,
namely, surface cuboidal cells and round stromal cells,
but also to neuroendocrine cells as the ‘third’ cell type.
In certain circumstances, the same molecular event of
PSH could facilitate the neuroendocrine phenotype dif-
ferentiation of respiratory epithelial progenitors of multi-
potency. The hypothesis is made based upon following
observations in our case: 1) although morphologically
distinctive, the two different components are so well
mingled that they cannot be distinguished either by radi-
ology or gross examination; 2) intimate mixture of PSH
and extensive PNC lesions are present throughout the
entire multi-nodular lesion; 3) the two different compo-
nents both express TTF-1 (a tissue-specific transcription
factor expressed by type II pneumocytes and Clara cells).
This ‘one tumor’ theory was further suggested by pre-
vious studies demonstrating different phenotype and
differentiation status of the two types of PSH cells and
neuroendocrine immunoactivity and neurosecretory gra-
nules in nested cells of PSH [6-8,17]. In addition, the re-
cent finding that PNCs share a common lineage with
alveolar cells [22] may further support that possibility
that this rare ‘third’ cell type and the other two may ori-
ginate from the same progenitor. This ‘one tumor’ the-
ory may be further validated if identical molecular
events could be shown in both PSH and PNC compo-
nents. Interestingly, the one and only reported case of
carcinoid tumors associated with PSH in the literature
described carcinoid tumors as completely separate from
PSH, with absence of PNC hyperplasia or carcinoid
tumorlets and completely negative staining for TTF-1 in
carcinoid tumor cells [9], which is different from our
case and may indicate other pathogenetic pathways.
Another intriguing feature of our case is the multiple
nodular presentation and unusually large size of PSH,
which could cause diagnostic difficulties for both clinicians
and radiologists. The sampling bias caused by the large
lesional area and multi-nodular growth pattern might lead
to pre-operative diagnostic errors for a lesion containing
more than one tumor component. In our case, the CT-
guided core needle biopsy only showed foci of PNC hyper-
plasia without a component of diagnostic PSH and no
confirmative diagnosis was made until after surgical resec-
tion. Multiple PSH is rare, accounting only for 3 to 4% of
all PSHs in large series and case reviews [3,5,11,27]. The
multiple tumors could locate within one or more than one
pulmonary lobe, unilaterally or bilaterally or even in pul-
monary fissures or the mediastinum, mimicking malignan-
cies or metastatic diseases. [3,5,27,28]. Those tumors were
usually completely resected by lobectomy or pulmonarywedge resection. So far, there were no reported cases of
lymph node metastasis, distal spread or malignant trans-
formation. Whether they were multicentric in origin or
intrapulmonary spread from one primary lesion is still
unclear. Multiple PSHs have also been reported to be as-
sociated with atypical adenomatous hyperplasia, which is
considered to be a forerunner of pulmonary adenocarcin-
oma [3,27]. Accumulation of such cases is needed to fur-
ther elucidate the histogenesis and biological behavior of
this rare entity.Conclusion
To our knowledge, this is the first described case of
mixed carcinoid and extensive neuroendocrine prolifer-
ation with multiple PSHs. Our patient received no post-
operative chemotherapy or radiation. No recurrence or
metastasis was identified during a 14-month follow-up.
Although PSH is generally considered a benign tumor,
the multi-nodular growth pattern and concurrence of
extensive PNC lesions in this case would justify long-term
post-operative surveillance. Whether PNC neoplasms and
PNC hyperplasia present in PSH as a simple combination
or a true component still remains a mystery. Further un-
derstanding of the molecular pathogenesis of these dis-
eases and more studies of similar tumor-combining cases
are required to unveil their potential intrinsic correlation
or cross-entity interaction. Although rare, PSH could pre-
sent in a multiple nodular form, mimicking malignancy in
imaging studies. Due to its rarity, the clinical behavior of
multiple PSHs is not yet well understood and further stud-
ies are needed to decide whether the lesions are multi-
centric in origin or a dissemination/metastasis from one
primary lesion.Consent
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